Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Incobotulinumtoxin A combined with fractional CO2 laser for peri-orbital syringoma
TCTR20261105003Phase 3Recruiting
- Sponsor
- Division of Dermatology, Department of Medicine Faculty of Medicine, Ramathibodi Hospital
- Start
- Feb 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, single-blind trial of botulinum toxin type A in syringoma (2 arms), sponsored by Division of Dermatology, Department of Medicine Faculty of Medicine, Ramathibodi Hospital. Primary endpoint: Volume of elevations at Week 32. Started Feb 2026; status: recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
syringoma
Beyond the preview
Go deeper on TCTR20261105003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20261105003.